Cat. No. | Product name | CAS No. |
DCC1830 |
Dmt-dalda
Potent and highly selective µ opioid agonist |
|
DCC1831 |
Dmxb-a
Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor |
148372-04-7 |
DCC1832 |
Dna Primase Inhibitor-1
Novel DNA primase inhibitor |
874787-49-2 |
DCC1833 |
Dna Primase Inhibitor-13
Novel DNA primase inhibitor |
261363-54-6 |
DCC1834 |
Dnac-1
Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens |
1006021-30-2 |
DCC1835 |
Dndi-0690
Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile |
|
DCC1836 |
Do-601
Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose |
100252-00-4 |
DCC1837 |
Dolastatin 10
Featured
Highly potent cytotoxic microtubule inhibitor |
110417-88-4 |
DCC1838 |
Doot-2d
Selective MAO-B inhibitor |
1522345-35-2 |
DCC1839 |
Dora 42
Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA) |
1030377-48-0 |
DCC1840 |
Doramectin
Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle |
117704-25-3 |
DCC1841 |
Dothiepin Hydrochloride
Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
25627-36-5 |
DCC1842 |
Dov51892
Agonist of GABAA receptors α15 subunits |
864673-91-6 |
DCC1843 |
Dp-326
Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections |
|
DCC1844 |
Dpa-154
Novel effective and selective inhibitor of E. coli topoisomerase I |
|
DCC1845 |
Dpb163-ae
Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum. |
|
DCC1846 |
Dpbx-l-dopa
Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors |
|
DCC1847 |
Dp-c-1
Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP |
|
DCC1848 |
Dpf-p10
First Potent Small Molecule Ligand for MALAT1 |
|
DCC1849 |
Dpi-287
Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects |
|
DCC1850 |
Dpp7-in-5385
Novel inhibitor of dipeptidyl peptidase 7 (DPP7) |
|
DCC1851 |
Dpp8/9-in-8j
Novel selective DPP8/9 inhibitor, blocking AML progression in vivo |